Free Trial

Lyell Immunopharma (LYEL) Competitors

Lyell Immunopharma logo
$17.00 -0.38 (-2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$17.02 +0.02 (+0.15%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LYEL vs. WVE, MAZE, IMTX, AMLX, IMNM, TRML, NUVB, TRVI, ARDX, and CVAC

Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include WAVE Life Sciences (WVE), Maze Therapeutics (MAZE), Immatics (IMTX), Amylyx Pharmaceuticals (AMLX), Immunome (IMNM), Tourmaline Bio (TRML), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Ardelyx (ARDX), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

Lyell Immunopharma vs. Its Competitors

Lyell Immunopharma (NASDAQ:LYEL) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Lyell Immunopharma has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.37, indicating that its share price is 237% less volatile than the S&P 500.

WAVE Life Sciences has higher revenue and earnings than Lyell Immunopharma. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lyell Immunopharma$60K5,442.83-$342.99M-$24.29-0.70
WAVE Life Sciences$93.95M13.33-$97.01M-$0.90-8.74

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by company insiders. Comparatively, 24.0% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, WAVE Life Sciences had 5 more articles in the media than Lyell Immunopharma. MarketBeat recorded 7 mentions for WAVE Life Sciences and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.01 beat WAVE Life Sciences' score of 0.71 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lyell Immunopharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
WAVE Life Sciences
1 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

WAVE Life Sciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. WAVE Life Sciences' return on equity of -78.45% beat Lyell Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lyell Immunopharma-552,328.31% -85.58% -68.85%
WAVE Life Sciences N/A -78.45%-41.51%

Lyell Immunopharma currently has a consensus price target of $15.00, suggesting a potential downside of 11.76%. WAVE Life Sciences has a consensus price target of $20.33, suggesting a potential upside of 158.37%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Lyell Immunopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lyell Immunopharma
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33
WAVE Life Sciences
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

WAVE Life Sciences beats Lyell Immunopharma on 12 of the 16 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LYEL vs. The Competition

MetricLyell ImmunopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$326.57M$3.02B$6.13B$10.46B
Dividend YieldN/A57.77%5.73%4.78%
P/E Ratio-0.7022.9185.1527.20
Price / Sales5,442.83612.09574.61178.68
Price / CashN/A172.6337.3961.86
Price / Book0.655.4112.396.65
Net Income-$342.99M$33.06M$3.32B$276.79M
7 Day Performance-9.91%-2.27%-0.24%-1.51%
1 Month Performance28.59%11.49%9.56%5.46%
1 Year Performance-32.00%-3.25%71.67%36.25%

Lyell Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LYEL
Lyell Immunopharma
1.2358 of 5 stars
$17.00
-2.2%
$15.00
-11.8%
-25.7%$326.57M$60K-0.70270Positive News
Short Interest ↑
WVE
WAVE Life Sciences
4.6947 of 5 stars
$7.94
+1.9%
$20.33
+156.2%
-5.5%$1.27B$108.30M-8.84240
MAZE
Maze Therapeutics
2.9096 of 5 stars
$28.67
+0.4%
$33.83
+18.0%
N/A$1.26B$167.50M0.00121Short Interest ↑
IMTX
Immatics
2.8626 of 5 stars
$10.32
+2.2%
$13.67
+32.5%
+14.1%$1.26B$168.65M-15.91260News Coverage
Analyst Upgrade
Analyst Revision
AMLX
Amylyx Pharmaceuticals
1.9488 of 5 stars
$14.05
-0.5%
$14.75
+5.0%
+300.8%$1.25B$87.37M-5.62200News Coverage
Analyst Forecast
IMNM
Immunome
1.6022 of 5 stars
$14.27
+0.1%
$23.20
+62.6%
+34.2%$1.24B$9.04M-4.6240
TRML
Tourmaline Bio
1.4964 of 5 stars
$47.90
0.0%
$45.65
-4.7%
+86.0%$1.23BN/A-13.9744Short Interest ↓
NUVB
Nuvation Bio
2.8127 of 5 stars
$3.57
-3.1%
$7.86
+120.4%
+62.0%$1.22B$7.87M-5.6760Analyst Forecast
Gap Up
TRVI
Trevi Therapeutics
2.4092 of 5 stars
$10.15
+4.5%
$21.75
+114.4%
+234.0%$1.22BN/A-23.8720
ARDX
Ardelyx
4.2322 of 5 stars
$5.05
+0.7%
$11.70
+131.9%
-14.1%$1.22B$333.61M-21.9890Analyst Revision
CVAC
CureVac
3.8437 of 5 stars
$5.38
-0.3%
$6.83
+27.1%
+92.2%$1.21B$579.18M5.60880

Related Companies and Tools


This page (NASDAQ:LYEL) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners